Drugs / Cladrabine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05780879 Background | Jun 2024 → Aug 2025 | acute myeloid leukemia | University of Michigan Rogel Cancer Center | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cladrabine | “Cladrabine (5mg/m2/day IV over 2 hours) has been substituted (CLAG)” NCT05780879 ↗ |
| Route | Intravenous | “Cladrabine (5mg/m2/day IV over 2 hours)” NCT05780879 ↗ |